Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Management of Urothelial Bladder Cancer in Clinical Practice: Real-World Answers to Difficult Questions.

Mar N, Dayyani F.

J Oncol Pract. 2019 Aug;15(8):421-428. doi: 10.1200/JOP.19.00215.

PMID:
31404517
2.

FGFR2-Altered Gastroesophageal Adenocarcinomas Are an Uncommon Clinicopathologic Entity with a Distinct Genomic Landscape.

Klempner SJ, Madison R, Pujara V, Ross JS, Miller VA, Ali SM, Schrock AB, Kim ST, Maron SB, Dayyani F, Catenacci DVT, Lee J, Chao J.

Oncologist. 2019 Jun 27. pii: theoncologist.2019-0121. doi: 10.1634/theoncologist.2019-0121. [Epub ahead of print]

PMID:
31249137
3.

Potential for the blood-based biomarkers cytokeratin 19 fragment (CYFRA 21-1) and human epididymal protein 4 (HE4) to detect recurrence during monitoring after surgical resection of adenocarcinoma of the lung.

Muley T, He Y, Rolny V, Wehnl B, Escherich A, Warth A, Stolp C, Schneider MA, Meister M, Herth FJ, Dayyani F.

Lung Cancer. 2019 Apr;130:194-200. doi: 10.1016/j.lungcan.2019.02.017. Epub 2019 Feb 19.

4.

Analysis of MDM2 Amplification: Next-Generation Sequencing of Patients With Diverse Malignancies.

Kato S, Ross JS, Gay L, Dayyani F, Roszik J, Subbiah V, Kurzrock R.

JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.17.00235. Epub 2018 Jul 13.

5.

The combination of the blood based tumor biomarkers cytokeratin 19 fragments (CYFRA 21-1) and carcinoembryonic antigen (CEA) as a potential predictor of benefit from adjuvant chemotherapy in early stage squamous cell carcinoma of the lung (SCC).

Muley T, Rolny V, He Y, Wehnl B, Escherich A, Warth A, Stolp C, Schneider MA, Dienemann H, Meister M, Herth FJ, Dayyani F.

Lung Cancer. 2018 Jun;120:46-53. doi: 10.1016/j.lungcan.2018.03.015. Epub 2018 Mar 17.

6.

Technical and clinical performance of a new assay to detect squamous cell carcinoma antigen levels for the differential diagnosis of cervical, lung, and head and neck cancer.

Holdenrieder S, Molina R, Qiu L, Zhi X, Rutz S, Engel C, Kasper-Sauer P, Dayyani F, Korse CM.

Tumour Biol. 2018 Apr;40(4):1010428318772202. doi: 10.1177/1010428318772202.

PMID:
29701125
7.

Carcinoembryonic antigen and cytokeratin-19 fragments for assessment of therapy response in non-small cell lung cancer: a systematic review and meta-analysis.

Holdenrieder S, Wehnl B, Hettwer K, Simon K, Uhlig S, Dayyani F.

Br J Cancer. 2017 Apr 11;116(8):1037-1045. doi: 10.1038/bjc.2017.45. Epub 2017 Mar 9. Review.

8.

Clinically Meaningful Use of Blood Tumor Markers in Oncology.

Holdenrieder S, Pagliaro L, Morgenstern D, Dayyani F.

Biomed Res Int. 2016;2016:9795269. doi: 10.1155/2016/9795269. Epub 2016 Nov 30. Review.

9.

Letter in response to: Identifying risk in the use of tumor markers to improve patient safety.

Dayyani F, Morgenstern D.

Clin Chem Lab Med. 2016 Dec 1;54(12):e383-e384. doi: 10.1515/cclm-2016-0335. No abstract available.

PMID:
27467754
10.

Diagnostic Performance of Risk of Ovarian Malignancy Algorithm Against CA125 and HE4 in Connection With Ovarian Cancer: A Meta-analysis.

Dayyani F, Uhlig S, Colson B, Simon K, Rolny V, Morgenstern D, Schlumbrecht M.

Int J Gynecol Cancer. 2016 Nov;26(9):1586-1593.

PMID:
27540691
11.

The combination of serum insulin, osteopontin, and hepatocyte growth factor predicts time to castration-resistant progression in androgen dependent metastatic prostate cancer- an exploratory study.

Dayyani F, Zurita AJ, Nogueras-González GM, Slack R, Millikan RE, Araujo JC, Gallick GE, Logothetis CJ, Corn PG.

BMC Cancer. 2016 Sep 6;16:721. doi: 10.1186/s12885-016-2723-1.

12.

TLE4 regulation of wnt-mediated inflammation underlies its role as a tumor suppressor in myeloid leukemia.

Shin TH, Brynczka C, Dayyani F, Rivera MN, Sweetser DA.

Leuk Res. 2016 Sep;48:46-56. doi: 10.1016/j.leukres.2016.07.002. Epub 2016 Jul 21.

13.

In Response to "Serum Tumor Marker Use in Patients With Advanced Solid Tumors".

Dayyani F, Morgenstern D, Holdenrieder S.

J Oncol Pract. 2016 Mar;12(3):273-4. doi: 10.1200/JOP.2015.009241. Epub 2016 Feb 2. No abstract available.

PMID:
26837562
14.

Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001).

Dragovich T, Laheru D, Dayyani F, Bolejack V, Smith L, Seng J, Burris H, Rosen P, Hidalgo M, Ritch P, Baker AF, Raghunand N, Crowley J, Von Hoff DD.

Cancer Chemother Pharmacol. 2014 Aug;74(2):379-87. doi: 10.1007/s00280-014-2499-4. Epub 2014 Jun 18.

15.

Management of advanced primary urethral carcinomas.

Dayyani F, Hoffman K, Eifel P, Guo C, Vikram R, Pagliaro LC, Pettaway C.

BJU Int. 2014 Jul;114(1):25-31. doi: 10.1111/bju.12630. Epub 2014 May 22. Review.

16.

Ligand-independent activation of MET through IGF-1/IGF-1R signaling.

Varkaris A, Gaur S, Parikh NU, Song JH, Dayyani F, Jin JK, Logothetis CJ, Gallick GE.

Int J Cancer. 2013 Oct 1;133(7):1536-46. doi: 10.1002/ijc.28169. Epub 2013 Apr 17.

17.

Increased serum insulin-like growth factor-1 levels are associated with prolonged response to dasatinib-based regimens in metastatic prostate cancer.

Dayyani F, Varkaris A, Araujo JC, Song JH, Chatterji T, Trudel GC, Logothetis CJ, Gallick GE.

Prostate. 2013 Jun;73(9):979-85. doi: 10.1002/pros.22645. Epub 2013 Jan 31.

18.

Combined Inhibition of IGF-1R/IR and Src family kinases enhances antitumor effects in prostate cancer by decreasing activated survival pathways.

Dayyani F, Parikh NU, Varkaris AS, Song JH, Moorthy S, Chatterji T, Maity SN, Wolfe AR, Carboni JM, Gottardis MM, Logothetis CJ, Gallick GE.

PLoS One. 2012;7(12):e51189. doi: 10.1371/journal.pone.0051189. Epub 2012 Dec 26.

19.

Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents.

Mao M, Tian F, Mariadason JM, Tsao CC, Lemos R Jr, Dayyani F, Gopal YN, Jiang ZQ, Wistuba II, Tang XM, Bornman WG, Bollag G, Mills GB, Powis G, Desai J, Gallick GE, Davies MA, Kopetz S.

Clin Cancer Res. 2013 Feb 1;19(3):657-67. doi: 10.1158/1078-0432.CCR-11-1446. Epub 2012 Dec 18.

20.

Plasmacytoid urothelial carcinoma, a chemosensitive cancer with poor prognosis, and peritoneal carcinomatosis.

Dayyani F, Czerniak BA, Sircar K, Munsell MF, Millikan RE, Dinney CP, Siefker-Radtke AO.

J Urol. 2013 May;189(5):1656-61. doi: 10.1016/j.juro.2012.11.084. Epub 2012 Nov 15.

21.

Retrospective analysis of survival outcomes and the role of cisplatin-based chemotherapy in patients with urethral carcinomas referred to medical oncologists.

Dayyani F, Pettaway CA, Kamat AM, Munsell MF, Sircar K, Pagliaro LC.

Urol Oncol. 2013 Oct;31(7):1171-7. doi: 10.1016/j.urolonc.2012.01.011. Epub 2012 Apr 24.

22.

Transcript profiling of CD16-positive monocytes reveals a unique molecular fingerprint.

Frankenberger M, Hofer TP, Marei A, Dayyani F, Schewe S, Strasser C, Aldraihim A, Stanzel F, Lang R, Hoffmann R, Prazeres da Costa O, Buch T, Ziegler-Heitbrock L.

Eur J Immunol. 2012 Apr;42(4):957-74. doi: 10.1002/eji.201141907.

23.

The role of HGF/c-Met signaling in prostate cancer progression and c-Met inhibitors in clinical trials.

Varkaris A, Corn PG, Gaur S, Dayyani F, Logothetis CJ, Gallick GE.

Expert Opin Investig Drugs. 2011 Dec;20(12):1677-84. doi: 10.1517/13543784.2011.631523. Epub 2011 Oct 28. Review.

24.

Novel therapies for metastatic castrate-resistant prostate cancer.

Dayyani F, Gallick GE, Logothetis CJ, Corn PG.

J Natl Cancer Inst. 2011 Nov 16;103(22):1665-75. doi: 10.1093/jnci/djr362. Epub 2011 Sep 13. Review.

25.

Prediction model for mortality after intracranial hemorrhage in patients with leukemia.

Dayyani F, Mougalian SS, Naqvi K, Shan J, Ravandi F, Cortes J, Weinberg J, Jabbour E, Faderl S, Wierda W, Thomas D, O'Brien S, Pierce S, Kantarjian H, Garcia-Manero G.

Am J Hematol. 2011 Jul;86(7):546-9. doi: 10.1002/ajh.22031. Epub 2011 Apr 20.

26.

Steps in prostate cancer progression that lead to bone metastasis.

Jin JK, Dayyani F, Gallick GE.

Int J Cancer. 2011 Jun 1;128(11):2545-61. doi: 10.1002/ijc.26024. Epub 2011 Mar 28. Review.

27.

Outcome of therapy-related acute promyelocytic leukemia with or without arsenic trioxide as a component of frontline therapy.

Dayyani F, Kantarjian H, O'Brien S, Pierce S, Jones D, Faderl S, Garcia-Manero G, Cortes J, Ravandi F.

Cancer. 2011 Jan 1;117(1):110-5. doi: 10.1002/cncr.25585. Epub 2010 Aug 27.

28.

Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC).

Dayyani F, Etzel CJ, Liu M, Ho CH, Lippman SM, Tsao AS.

Head Neck Oncol. 2010 Jun 29;2:15. doi: 10.1186/1758-3284-2-15. Review.

29.

Cause of death in patients with lower-risk myelodysplastic syndrome.

Dayyani F, Conley AP, Strom SS, Stevenson W, Cortes JE, Borthakur G, Faderl S, O'Brien S, Pierce S, Kantarjian H, Garcia-Manero G.

Cancer. 2010 May 1;116(9):2174-9. doi: 10.1002/cncr.24984.

30.

Mutations in the neutral sphingomyelinase gene SMPD3 implicate the ceramide pathway in human leukemias.

Kim WJ, Okimoto RA, Purton LE, Goodwin M, Haserlat SM, Dayyani F, Sweetser DA, McClatchey AI, Bernard OA, Look AT, Bell DW, Scadden DT, Haber DA.

Blood. 2008 May 1;111(9):4716-22. doi: 10.1182/blood-2007-10-113068. Epub 2008 Feb 25.

31.

HIV-associated multicentric Castleman's disease.

Stebbing J, Pantanowitz L, Dayyani F, Sullivan RJ, Bower M, Dezube BJ.

Am J Hematol. 2008 Jun;83(6):498-503. doi: 10.1002/ajh.21137. Review.

32.

Loss of TLE1 and TLE4 from the del(9q) commonly deleted region in AML cooperates with AML1-ETO to affect myeloid cell proliferation and survival.

Dayyani F, Wang J, Yeh JR, Ahn EY, Tobey E, Zhang DE, Bernstein ID, Peterson RT, Sweetser DA.

Blood. 2008 Apr 15;111(8):4338-47. doi: 10.1182/blood-2007-07-103291. Epub 2008 Feb 7.

33.

Multicentric Castleman's disease masquerading as HIV-related lymphoma.

Dayyani F, Pantanowitz L, Sandridge TG, Sullivan RJ, Dezube BJ.

Am J Med Sci. 2007 Oct;334(4):317-9.

PMID:
18030193
34.

Delineation of the minimal commonly deleted segment and identification of candidate tumor-suppressor genes in del(9q) acute myeloid leukemia.

Sweetser DA, Peniket AJ, Haaland C, Blomberg AA, Zhang Y, Zaidi ST, Dayyani F, Zhao Z, Heerema NA, Boultwood J, Dewald GW, Paietta E, Slovak ML, Willman CL, Wainscoat JS, Bernstein ID, Daly SB.

Genes Chromosomes Cancer. 2005 Nov;44(3):279-91.

PMID:
16015647
35.

The HMG-CoA reductase inhibitor simvastatin overcomes cell adhesion-mediated drug resistance in multiple myeloma by geranylgeranylation of Rho protein and activation of Rho kinase.

Schmidmaier R, Baumann P, Simsek M, Dayyani F, Emmerich B, Meinhardt G.

Blood. 2004 Sep 15;104(6):1825-32. Epub 2004 May 25.

PMID:
15161667
37.

Autologous stem-cell transplantation restores the functional properties of CD14+CD16+ monocytes in patients with myeloma and lymphoma.

Dayyani F, Joeinig A, Ziegler-Heitbrock L, Schmidmaier R, Straka C, Emmerich B, Meinhardt G.

J Leukoc Biol. 2004 Feb;75(2):207-13. Epub 2003 Oct 23.

PMID:
14576364
38.

Treosulfan is an effective inducer of cell death in myeloma cell lines and primary myeloma cells from patients.

Meinhardt G, Dayyani F, Jahrsdörfer B, Baumgart J, Emmerich B, Schmidmaier R.

Br J Haematol. 2003 Sep;122(6):892-9.

PMID:
12956758
39.

Mechanism of glucocorticoid-induced depletion of human CD14+CD16+ monocytes.

Dayyani F, Belge KU, Frankenberger M, Mack M, Berki T, Ziegler-Heitbrock L.

J Leukoc Biol. 2003 Jul;74(1):33-9.

PMID:
12832440
40.

The proinflammatory CD14+CD16+DR++ monocytes are a major source of TNF.

Belge KU, Dayyani F, Horelt A, Siedlar M, Frankenberger M, Frankenberger B, Espevik T, Ziegler-Heitbrock L.

J Immunol. 2002 Apr 1;168(7):3536-42.

41.

Selective mobilization of CD14(+)CD16(+) monocytes by exercise.

Steppich B, Dayyani F, Gruber R, Lorenz R, Mack M, Ziegler-Heitbrock HW.

Am J Physiol Cell Physiol. 2000 Sep;279(3):C578-86.

Supplemental Content

Loading ...
Support Center